Long Distance Contribution to s→dγs \to d\gamma and Implications for Ω−→Ξ−γ,Bs→Bd∗γ\Omega^-\to \Xi ^-\gamma, B_s \to B_d^*\gamma and b→sγb \to s\gamma

We estimate the long distance (LD) contribution to the magnetic part of the $s \to d\gamma$ transition using the Vector Meson Dominance approximation $(V=\rho,\omega,\psi_i)$. We find that this contribution may be significantly larger than the short distance (SD) contribution to $s \to d\gamma$ and could possibly saturate the present experimental upper bound on the $\Omega^-\to \Xi^-\gamma$ decay rate, $\Gamma^{\rm MAX}_{\Omega^-\to \Xi^-\gamma} \simeq 3.7\times10^{-9}$eV. For the decay $B_s \to B^*_d\gamma$, which is driven by $s \to d\gamma$ as well, we obtain an upper bound on the branching ratio $BR(B_s \to B_d^*\gamma)<3\times10^{-8}$ from $\Gamma^{\rm MAX}_{\Omega^-\to \Xi^-\gamma}$. Barring the possibility that the Quantum Chromodynamics coefficient $a_2(m_s)$ be much smaller than 1, $\Gamma^{\rm MAX}_{\Omega^-\to \Xi^-\gamma}$ also implies the approximate relation $\frac{2}{3} \sum_i \frac{g^2_{\psi_i}(0)}{m^2_{\psi_i}} \simeq \frac{1}{2} \frac{g^2_\rho(0)}{m^2_\rho} + \frac{1}{6}\frac{g^2_\omega(0)}{m^2_\omega}$. This relation agrees quantitatively with a recent independent estimate of the l.h.s. by Deshpande et al., confirming that the LD contributions to $b \to s\gamma$ are small. We find that these amount to an increase of $(4\pm2)\%$ in the magnitude of the $b \to s \gamma$ transition amplitude, relative to the SD contribution alone.Comment: 16 pages, LaTeX fil

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Feasibility of in vivo MR elastographic splenic stiffness measurements in the assessment of portal hypertension

10.2214/AJR.07.3504American Journal of Roentgenology1931122-127AJRO